Companies /Healthcare

Standard BioTools Inc

NASDAQ: LAB Medical Devices
$0.69
▲ $0.02 (+2.85%) today
Markets closed · 12:28pm ET

LAB at a Glance

Valuation
Market cap
$263.1M
Profitability
Revenue (TTM)
$84.6M
Profit margin
100.4%
EPS (TTM)
$-0.13
Price
52-week range
$1 – $2
Street target
$1.35
Earnings
Next report
Nov 3, 2026

Headquartered in Boston, MA Fiscal year ends December NASDAQ: LAB standardbio.com

About Standard BioTools

Standard BioTools Inc. (NASDAQ: LAB) provides life science tools through its portfolio of next-generation solutions designed to help biomedical researchers develop better therapeutics faster. The company generates revenue from three categories: Instruments, Consumables, and Services (predominantly field services). Standard BioTools is currently pursuing a merger with Treeline Biosciences, a therapeutics company, and has agreed to divest its Mass Cytometry business. The company previously acquired SomaLogic and has settled contingent payment obligations with Illumina related to that acquisition. Updated

LAB Coverage

Frequently Asked Questions

What does Standard BioTools do?

Standard BioTools Inc. (NASDAQ: LAB) provides life science tools through its portfolio of next-generation solutions designed to help biomedical researchers develop better therapeutics faster. The company generates revenue from three categories: Instruments, Consumables, and Services (predominantly field services).

What is the LAB stock price target?

The Wall Street consensus 12-month price target for LAB is $1.35.